STOCK TITAN

Cyteir Therapeutics to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

LEXINGTON, Mass.--(BUSINESS WIRE)-- Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference, being held virtually on September 10, 2021, at 11:45am ET.

A live webcast of the fireside chat will be available in the Investors & Media section of the Cyteir website at www.cyteir.com. A webcast replay will also be available on the website shortly after conclusion of the event for 30 days.

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

INVESTOR CONTACT:

Lisa Hayes

Vice President, Investor Relations and Corporate Communications

908-868-8926

Lisa.Hayes@cyteir.com



MEDIA CONTACT:

Michele Parisi

925-429-1850

mparisi@forwardhealthinc.com

Source: Cyteir Therapeutics

Cyteir Therapeutics Inc

NASDAQ:CYT

CYT Rankings

CYT Latest News

CYT Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About CYT

through a unique cancer treatment approach, cyteir therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. currently in development, is the answer to the oncology triumvirate: reducing side effects, reducing therapy resistance, inducing diseased cell self destruction.